Lantern is a leader in the development of tech-bio to deliver the next generation of cancer medicines, where success is defined by both AI-driven progress and meaningful patient outcomes," said Panna ...
In this episode presented by DIA, BioSpace's head of insights Lori Ellis discusses the evolution of women's inclusion in ...
Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company with clinical development programs focusing on organ fibrosis, today announced the publication ...
The Company will host a corporate update conference call on Monday, March 31, 2025 at 4:30 PM ET following its presentation of results from the CardiAMP HF Trial at the Late-Breaking Clinical Trials ...
vTv Therapeutics, a biopharmaceutical company based in High Point, has received clearance from the U.S. Food and Drug ...
Avant Technologies Inc. (OTCQB:AVAI) (”Avant” or the “Company”), and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease ...
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugsRamat Gan, Israel, March 24, 2025 (GLOBE ...
Increasingly, protocol stack development is subjected to constant requirements changes arising from evolving technical standards, changing customer needs and diverse deployment scenarios coupled with ...
Abstract: Today, functional verification consumes most of the time in the design of layered protocols like OSI Model ... 5th section will cover the development of verification environment for XAUI ...
--(BUSINESS WIRE)--TIXiMED Inc. (www.tiximed.com), a clinical-stage pharmaceutical company based on the breakthrough discovery that TXNIP plays an important role in the development and progression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback